ViGeneron

ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians University of Munich. ViGeneron dedicated to develop innovative gene therapies based on our two unique and proprietary technology platformsIn November 2019, the company announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China

Anteris Technologies Ltd (formerly known as Admedus (formerly known as Allied Healthcare Group Ltd), through its subsidiary Admedus Vaccines (formerly Coridon)), is a structural heart company delivering clinically superior solutions, focused on the development of next-generation technologies with world class partners.In July 2010, Australian medical devices company, Allied Medical, planned to acquire a 38.6% controlling stake in Coridon via a AUD $3 million (US $2.6 million) rights issue. Under the agreement, Allied Medical could acquire up to 55.7% interest. In June 2011 BioMD and Allied Medical Ltd were merged to form Allied Healthcare Group. In April 2012, Allied Healthcare held a 44% stake in Coridon. In July 2013, Allied Healthcare increased the stake in Coridon from 44 to 50.1%.In February 2023, Anteris Technologies Ltd completed equity fundraising, as a result of which the company issued 1.458 million new ordinary shares at an issue price of $24.00

Atb Therapeutics is a developer of monoclonal antibodies from plant cells designed to treat cancer